Acquisition Upsell SAMDI Tech was acquired by Charles River in early 2023, creating an immediate opportunity to position SAMDI’s label-free HTS MS capabilities as an integrated part of Charles River’s drug discovery services and client base.

HTS MS Platform Highlight SAMDI’s rapid, quantitative SAMDI technology as a differentiator for high-throughput, label-free screening to accelerate go/no-go decisions, offering a compelling add-on for CROs and biopharma clients seeking faster decision cycles.

Small Library Expansion Leverage past partnerships to expand small molecule libraries and augment existing platforms; propose collaborations that combine SAMDI’s chemistry libraries with broader screening capabilities under Charles River’s ecosystem.

Low Revenue Upside Current revenue is under one million, signaling an opportunity to craft targeted value propositions and scalable service bundles that can grow with the combined enterprise and its client network.

Strategic Fit Position as a gateway to Charles River’s extensive client base and integrated drug discovery solutions, offering SAMDI’s technology as a practical enhancement to existing workflows, with potential for co-sponsored marketing and joint ventures.